Vaccibody: First 10 patients enrolled and vaccination started

Our portfolio company Vaccibody has released an update on the clinical trial of their neoantigen cancer vaccine in phase I/II: 10 patients have been enrolled and vaccination has started.

 

Mads Axelsen, MD, Chief Medical Officer in Vaccibody, said in a press release:

We are very pleased with the enrollment in the neoantigen trial and with the interest we are experiencing from clinical investigator and from patients. To that end I would like to thank the experienced cancer experts and investigators in this trial namely Prof. Jürgen Krauss from Heidelberg, Prof. Angela Krackhardt from Munich and Prof. Elke Jäger from Frankfurt. Together with their dedicated teams they are doing an outstanding job with the neoantigen trial.”

 

Read more on Vaccibody´s home page.

 

Targovax: Encouraging interim results of ONCOS-102

Our portfolio company Targovax has released interim results from the phase I trial of ONCOS-102 in checkpoint inhibitor refractory melanoma.

 

Dr. Magnus Jäderberg, CMO of Targovax, said in a press release from the company:

“Given the limited number of patients who have completed the study to date, it is encouraging to already see a complete response to ONCOS-102 primed KEYTRUDA® treatment in this CPI refractory patient population. This case is particularly interesting, as the patient became refractory to KEYTRUDA® before entering our trial. At the same time, five patients progressed, which we believe may be partly due to an insufficient number of ONCOS-102 injections. Consequently, we have agreed with the investigators to expand the trial with additional patients, who will receive an increased number of ONCOS-102 injections. The complete response, combined with the optimized dosing regimen, makes us optimistic that we may demonstrate the full potential of ONCOS-102 in the checkpoint inhibitor refractory setting.”

 

Read more on the Targovax´web site.

Vaccibody in collaboration with prestige company Nektar Therapeutics

Our portolio company Vaccibody AS just entered a clinical collaboration with U.S. company Nektar Therapeutics.

 

The aim of the collaboration is to evaluate Vaccibody’s personalized cancer neoantigen vaccine, VB10.NEO, in combination with Nektar’s immune treatment NKTR-214, which is a CD-122-biased agonist.

In an interview with Norwegian financial paper “Finansavisen”, President and CSO  in Vaccibody, Agnete Brunsvik Fredriksen, states that the agreement means a lot to Vaccibody, since Nektar Therapeutics is among the hottest immunotherapy companies around.

Nektar Therapeutics is registered on Nasdaq and has a market cap of $10 billion. In February 2018 Nektar entered a collaborative deal with Bristol-Myers Squibb to furter develop NKTR-214 .

Jonathan Zalevsky, CSO of Nektar Therapeutics, said:

Vaccibody technology holds the potential of combining a personalized cancer vaccine approach which is designed to drive antigen presentation with NKTR-214, which can drive specific clonal T cell expansion to vaccine epitopes. We look forward to working with Vaccibody to seek the advancement of this unique combination into the clinic.

 

Positive preclinical  results

VB10.NEO is designed to specifically activate the patient’s immune system to tumour specific antigens, called neoantigens. NKTR-214 is designed to lead to further stimulation and proliferation of the immune cells. Preclinical results indicate a synergistic effect of VB10.NEO and NKTR-214 resulting in enhanced neoantigen-specific T cell responses. The clinical evaluation will take place in patients with squamous cell carcinoma of the head and neck. The first stage of the clinical trial will be a pilot study which will enroll 10 patients.

Nektar and Vaccibody each will maintain ownership of their own compounds in the clinical collaboration, and the two companies will jointly own clinical data that relate to the combination of VB10.NEO and NKTR-214. Under the terms of the agreement and following the completion of the pilot study, the two companies will evaluate next steps for development of the combination regimen.

Martin Bonde, CEO of Vaccibody, commented:

We are very pleased to be joining forces with Nektar Therapeutics in this new clinical research collaboration. The preclinical in-vivo studies of NKTR-214 in combination with Vaccibody’s neoantigen vaccines generated very promising results. We look forward to further evaluate the Vaccibody neoantigen vaccine in combination with NKTR-214 in the clinic. The combination is designed to improve clinical outcome in patients that need additional help to elicit a strong, neoantigen-focused immune response and thus such combination may broaden the patient population benefitting from either therapy alone.

 

 

Facts:

About VB10.NEO

VB10.16, is a Vaccibody proprietary therapeutic DNA vaccine which uses private neoantigens for the personalized treatment of cancer patients. A phase I/IIa neoantigen clinical trial is currently enrolling patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell carcinoma as well as urothelial or squamous cell carcinoma off head and neck.

 

About Vaccibody AS

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. A phase I/IIa neoantigen clinical trial is now enrolling patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell carcinoma as well as urothelial or squamous cell carcinoma off head and neck. Vaccibody’s front runner program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first-in-human study (phase I/IIa), which is now fully enrolled, evaluates the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3).

www.vaccibody.com

Source: Vaccibody and Finansavisen

Vi feirer 50 episoder med podkast

Vi har nå kommet til episode 50 i vår podkast RADIUM. Det feires med en live innspilling. Vi skal snakke om et tema som RADFORSK er veldig engasjert i, nemlig kliniske studier. Studiene er helt avgjørende for å utvikle kreftbehandling, og det er enormt viktig at norske kreftpasienter får ta del i dette. 

 

I løpet av halvannet år har Jónas Einarsson, CEO i RADFORSK og Elisabeth Kirkeng Andersen, kommunikasjonsansvarlig i RADFORSK, poddet hele 49 ganger om kreft, kreftforskning og utvikling av kreftbehandling blant porteføljebedriftene til RADFORSK. Hver episode blir lyttet til av mellom 800 og 3000 lyttere.

Episode 50 må derfor feires. Vi går live i Kreftforeningens Vitensenter og får med oss en rekke gjester til å snakke om kliniske studier: Hva er det, hvorfor er de så viktige, hvorfor er det viktig å gjøre kliniske studier i Norge – og hvordan skal vi få flere kliniske studier til Norge.

Kom og bli med på feiringen! Still spørsmål direkte til oss og til gjestene på sms.

 

Program

Vi starter kl 15:00 og er ferdig kl 17:00, dørene åpner 14:30.

  • Maiken Engelstad, spesialrådgiver i helse- og omsorgsdepartementet
  • Øyvind Kongstun Arnesen, CEO Ultimovacs og styreleder i Oslo Cancer Cluster
  • Katrine Bryne, spesialrådgiver i LMI
  • Kirsten Haugland eller Anne Lise Ryel fra Kreftforeningen

Meld deg på her eller kom innom om du er i nærheten.

 

 

Podkasten Radium går live – og vi vil se deg!

Podkasten Radium forflytter seg ut av studioet i Oslo Cancer Cluster Innovasjonspark til Kreftforeningens Vitensenter to ganger nå i mars. Vi håper å se deg blant publikum!

 

Sammen med Kreftforeningen arrangerer vi to live podkaster i mars.
Se info om seminarene nedenfor:

 

Investering med hode og hjertet

Meld deg på her

Temaet for live innspillingen er investeringer i selskaper som utvikler kreftbehandling spesielt, men vi ser og på større deler av helseindustrien.

Gjestene og tematikken for innspillingen er; erfarne investorer som forteller om sine kriterier når de investerer, hvorfor investering i disse selskapene er å investere med hjertet og hodet, samt nytt fra to av selskapene i porteføljen til RADFORSK. Her er det mye kunnskap og tips å hente opp får både investorer og oppstartsbedrifter.

I tillegg kan du stille spørsmål via sms. Og vi serverer lett frokost!

Program

Dag: 16. mars
Tid: 8:30 – 10:00
Dørene åpner kl 8:00 og vi serverer kaffe og lett frokost
Sted: Kreftforeningens Vitensenter, Kongens gate 6 i Oslo sentrum

Meld deg på her.

 

Moderatorer:
Elisabeth Andersen og Jónas Einarsson fra podkasten Radium

 

Første panel:
Hvorfor velge å investere med hode og hjertet?

•    Anne Lise Ryel, Generalsekretær i Kreftforeningen

 

Andre panel:
Hva er kriteriene for å investere i et biotek/kreftselskap – vi spør ekspertene.

•    Ingrid Teigland Akay, Managing Partner Hadean Ventures

•    Hans Ivar Robinson, CEO Birk Ventures

 

Tredje panel: Selskaper fra RADFORSK sin portefølje presenterer seg:

•    Per Walday, CEO PCI Biotech

•    Agnete Fredriksen, President og CSO Vaccibody

 

Persontilpasset kreftbehandling: Hvordan få kunnskapen og teknologien hele veien til pasientene?

Norsk forskning og teknologi kan i nær framtid bidra til at kreftpasienter får rett behandling til rett tid, tilpasset sin kreftform, såkalt persontilpasset kreftmedisin. Forutsatt at sykehusene tar forskningsresultatene og den nye teknologien i bruk.

 

Meld deg på her.

I denne live innspillingen av podkasten Radium, så kommer to av Norges fremste forskere for å snakke med Jónas Einarsson og Elisabeth Kirkeng Andersen: Professor Erik Fosse og professor Håvard Danielsen vil fortelle oss om de siste teknologiske gjennombruddene fra to fyrtårnprosjekter som kobler digitalisering med dyp medisinsk forståelse for å utvikle persontilpasset kreftmedisin: BigMed og DoMore!

Hva betyr forskningen for behandling av kreftpasienter? Og hvordan kan vi sikre at for at resultatene tas i bruk? Det skal generalsekretær i Kreftforeningen, Anne Lise Ryel og Ketil Widerberg, daglig leder av Oslo Cancer Cluster, snakke om.

BigMed og DoMore! er begge forskningsprosjekter som er støttet fra Forskningsrådet med over 50 millioner kroner hver seg. Se mer om DoMore! og BigMed nederst i artikkelen.

Vi åpner for spørsmål fra salen på sms.

 

PRAKTISK INFO:

Dag: 21. mars

Tid: 17:00 – 18:30, Dørene åpner 16:30 og vi tilbyr lett bevertning

Sted: Kreftforeningens Vitensenter, Kongens gate 6 i Oslo sentrum

Meld deg på her.

 

PROGRAM:

Moderatorer: Jónas Einarsson og Elisabeth Kirkeng Andersen, RADFORSK og podkasten Radium

 

Persontilpasset kreftmedisin er rett rundt hjørnet: Hva skjer i to av Norges fremste forskningsprosjekter innen området?

  • Professor Håvard Danielsen, leder av DoMore! og Institutt for kreftgenetikk og informatikk ved Oslo universitetssykehus
  • Professor Erik Fosse, leder av BigMed og Intervensjonssenteret ved Oslo universitetssykehus

Norske kreftpasienter trenger at forskning og innovasjon tas i bruk i sykehus-Norge

  • Anne Lise Ryel, generalsekretær i Kreftforeningen
  • Ketil Widerberg, daglig leder Oslo Cancer Cluster

 

FAKTA: 

Om BigMed:

«BigMed er et omfattende IKT-prosjekt forankret hos Oslo Universitetssykehus. Prosjektet er et samarbeid som involverer partnere fra pasientorganisasjoner, klinikk, akademia og næringslivet. Formålet er å adressere barrierer for utviklingen av persontilpasset medisin i Norge og legge til rette for persontilpasset medisin ved bruk av stordatametoder. Prosjektet er finansiert av Norges Forskningsråd og prosjektets partnere»

Leder for BigMed er Erik Fosse, professor i medisin ved Universitetet i Oslo og spesialist i generell kirurgi og hjertekirurgi. Fosse leder Intervensjonssenteret ved Rikshospitalet, som er en forsknings- og utprøvningsavdeling for ny teknologi innen medisinsk behandling.

www.bigmed.no

 

Om DoMore:

Over- og underbehandling av kreft er en belastning for pasienter og samfunn. Som ett av Forskningsrådets tre fyrtårnsprosjekter er oppdraget i DoMore! å løse denne store samfunnsutfordringen gjennom nye IKT-løsninger. Forskerne i prosjektet utvikler datamaskiner som skal kunne gi langt bedre svar på hva som foregår i en svulst enn spesialistene kan med dagens metoder. 7000 pasienter og 20 000 prøver er allerede inkludert i studien som omfatter prostata- tarm og lungekreft. Til sammen utgjør disse formene 44 prosent av alle kreftdødsfall. Målet er å kunne tilby nye og langt mer effektive systemer for diagnostisering og prognostisering av kreft allerede innen 2021.

www.domore.no

 

Leder for DoMore! er Håvard E. Danielsen, genetiker med en ph.d. i medisin og professor ved Institutt for informatikk ved Universitetet i Oslo og instituttleder for kreftgenetikk og informatikk ved Oslo universitetssykehus. I 2017 ble han tildelt tittelen gjesteprofessor ved Universitetet i Oxford. Hovedfokus i forskningen hans er DNA- og kromatin organisasjon og bruk av informatiske verktøy for å forstå genomiske endringer i kreft.

 

Om RADFORSK og Radium:
I podkasten RADIUM snakker Jónas Einarsson og Elisabeth Kirkeng Andersen om kreft, kreftforskning og porteføljeselskapene i RADFORSK. RADFORSK er et eviggrønnt investeringsselskap som etablerer og har aktivt eierskap i bedrifter som utvikler kreftbehandling.

Zelluna Immunotherapy appoints Miguel Forte as CEO

Our portfolio company Zelluna Immunotherapy has appointed Miguel Forte as chief executive officer (CEO) to drive Zelluna through next stage of international clinical-phase development.

 

Zelluna Immunotherapy is a biotechnology company specializing in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need.

“Zelluna has a very strong foundation, based on over 30 years of cutting edge research. As a result, Zelluna now has a unique offering, both in the sourcing of its TCRs and its development partnerships and pathways,” said Miguel Forte, CEO, Zelluna.

“I wished to join Zelluna to combine my experience to the considerable potential of Zelluna to position it as an international immunotherapy leader and bringing serious therapeutic options to patients of the most common and fatal solid cancers.”

Zelluna selected Miguel Forte as CEO due to his extensive commercial experience in the regenerative medicine, cell therapy, medical and regulatory affairs industries. Miguel is also currently chief commercialization officer and chair of the commercialization committee for the International Society of Cellular Therapy, the global society of clinicians, researchers, regulatory specialists, technologists and industry partners in the cell therapy sector. Zelluna will utilize Miguel’s operational expertise in the development pipeline, from early and late stage clinical trials to market authorization and the launch of new biologic products for various indications.

 

Unique company developing TCRs based on long-time survivors

“Zelluna is developing a unique immunotherapy portfolio of non-engineered tumor specific T-cell receptors (TCRs) isolated from long term survivors from cancer vaccine trials conducted by former professor Gustav Gaudernack’s group at the Oslo University Hospital. This enables Zelluna to target some of the most common cancer antigens and cancer types. Its established partnerships also grant critical support including all capabilities of TCR development, one of Europe’s largest academic GMP cell therapy production facilities headed by professor Gunnar Kvalheim, and access to patients and clinical trial support through a dedicated Clinical Trial Unit,” said Anders Tuv, chairman of the board, Zelluna.

One of the main initial tasks for Miguel will be to lead Zelluna through its next stage of development by driving clinical translation of the TCR pipeline, developing new international scientific and commercial partnerships and forging relationships with the international investor communities. This includes positioning Zelluna’s therapeutic candidates in the context of the adoptive cell therapy market for targeted lymphocytes, development of off-the-shelf cell products and soluble TCR based biologics.

“Appointing a CEO with the international experience and profile of Miguel Forte will be critical to further enhance the therapeutic, development and commercial potential of Zelluna, and push its leadership position in the international TCR and immunotherapy marketplaces,” said Tuv.

Specifically, Miguel’s experience at Bone Therapeutics and TxCell will be important, where he contributed to transforming TxCell into a quoted cell therapy company and major commercial and scientific partnerships. Miguel  will also contribute his experience forged at the European Medicines Agency, Bristol-Myers Squibb, Abbott and Wellcome Laboratories (now part of GSK), Nabi Pharmaceuticals and UCB.

 

About Zelluna Immunotherapy

Zelluna Immunotherapy specializes in immunotherapies targeting a broad range of solid cancers with a high unmet medical need. The company is developing a unique portfolio of non-engineered tumor specific T-cell receptors (TCRs) isolated from long term surviving patients from cancer vaccine trials. The TCRs combine specificity and affinity to have the potential for a safe and efficient therapy to target a variety of common cancer types. Zelluna has a long term CRADA with the Department for Cell Therapy at Oslo University Hospital (OUH), providing comprehensive capabilities of TCR development, ranging from lead discovery to clinical translation. The owners of Zelluna are Radforsk, Inven2, Birk Venture, RO Invest and Prieta.

For more information, please visit www.zelluna.com.

 

Source: Zelluna Immunotherapy 

 

 

Kronikk i Aftenposten

Sent i september hadde Jónas Einarsson en kronikk i Aftenposten der han ber myndigheter og legemiddelindustri komme opp av skyttergravene og snakke med hverandre.

Årsaken er at det nåværende systemet for innkjøp og prissetting ikke fungerer, og at pasientene blir de skadelidende. Du kan lese hele kronikken nedenfor.

 


Ikke kjeft. Snakk med hverandre

Av Jónas Einarsson, administrerende direktør Radiumhospitalets Forskningsstiftelse

 

Mediaoppslag rundt kreftpasienter og nye medisiner er blitt hverdagskost. I 2012 sto 20 år gamle Matias Wilberg fram da han ikke fikk immunterapibehandlingen ipilimumab mot sin føflekkreft. Etter Wilberg har vi gjennom mediene møtt et utall kreftpasienter som venter på kreftmedisiner som er godkjente, men som ikke blir tatt i bruk i Norge. Selv om helseminister Bent Høie har tatt viktige grep, så gjør han ikke nok. Dagens modell for innkjøp og prissetting av legemidler fungerer ikke.

 

Bekymret på vegne av kreftpasientene: Jeg har arbeidet som allmennlege i 18 år og ledet Radiumhospitalets Forskningsstiftelse, Radforsk, i 17 år. Radforsk er et investeringsselskap som etablerer og utvikler bedrifter som kommersialiserer kreftforskning. Vi har 11 selskaper i vår portefølje, noen av dem med produkter på markedet, noen i klinisk utvikling. Vi fungerer som en eviggrønn investor, og alt overskudd blir pløyd tilbake til kreftforskning. Vi står og bak Oslo Cancer Cluster, Oslo Cancer Cluster Inkubator og Oslo Cancer Cluster Innovasjonspark.

 

Paradigmeskifte fra død til kronisk sykdom: Vi som lever i dag er så heldige at vi får oppleve et paradigmeskifte innen utvikling av ny kreftbehandling. Selv om for mange dør av kreft, så øyner vi en ny ære. Ny kreftbehandlinger kurerer flere kreftpasienter og gjør mange til kronikere. Paradigmeskiftet skyldes en dypere biologisk forståelse av hva kreft egentlig er. En kø av kreftlegemidler utvikles nå basert på immunterapi. Vi går bort fra å behandle kreft i organer, til å sikte rett på målet, uavhengig av hvor svulsten sitter.

 

Samfunnskontrakt for utvikling av medisiner: Å utvikle legemidler er dyrt, det er høy risiko og det tar lang tid. Derfor er det laget en samfunnskontrakt mellom offentlig og privat sektor for utvikling av legemidler. Det offentlige står for den medisinske grunnforskningen. Privat sektor, ved investorer, biotekselskaper og legemiddelindustri, står for finansieringen fram til markedet. Det private får kompensasjon av myndighetene i form av patentering eller markedekslusivitet for legemiddelet i én tidsperiode. Etter dette kan konkurrenter få tilgang til oppskriften, og utvikle sine egne produkter billigere, såkalt generika. Novartis lanserte Glivec for behandling av blodkreftsydkommen KLM i 2001. Glivec var en revolusjon. Over 90 % lever fem år etter diagnosen. Tidligere var sykdommen en dødsdom. I 2016 gikk patentet på Glivec ut i USA. En studie* estimerer at kostnaden ved å bruke legemiddelet for én pasient vil gå fra 60 000 USD per år til 6 000 USD med bruk av generika. Prisen vil etter all sannsynlighet gå ned i samme størrelsesorden i Norge.

 

Industrien må jenke seg og myndighetene må komme dem i møte: Tidligere kunne det ta 10-20 år, koste opp mot én milliard dollar å utvikle en medisin. Nå går denne utviklingen raskere fordi medisinene testes på færre pasienter. Det betyr at kostnadene går betraktelig ned. Derfor er det ikke lengre bærekraftig å kreve én million kroner for ett legemiddel. Legemiddelindustrien skal dog få godt betalt, slik at overskuddet brukes til å utvikle nye medisiner.

 

Kan ikke si både ja og nei: Det store paradokset i Norge nå, er at politikerne på den ene siden ser til helsenæringen som ny næring. Myndigheten sier på den andre siden at de ikke ønsker å betale for produktene som næringen utvikler. Min oppfordring nå er; Myndighetene, legemiddelindustrien og fagfolk må begrave stridsøksen og sammen utvikle en ny modell for innkjøp og prissetting av legemidler. Konsekvensen av å ikke ta dette på alvor, kan være at samfunnskontrakten mellom det private og det offentlige for utvikling av nye legemidler kollapser. De skadelidende blir helsenæringen vi bygger opp i Norge og kreftpasienter, som vi vil fortsette å møte i media.

 

 

 

* https://academic.oup.com/jnci/article/108/7/djw003/2412626/Cost-effectiveness-of-Tyrosine-Kinase-Inhibitor?searchresult=1

View video´s from our events @ Oslo Innovation Week

Radforsk co-hosted three cancer-related events during Oslo Innovation Week and Forskningsdagene. If you missed out, you may watch them now.

Together with our partners the Norwegian Cancer Society, Oslo Cancer Cluster, IBM Norway, Cancer Research UK, Norway Health Tech and EAT, we hosted these events.

We had great audiences during our three events on the 27th and 28th of September. If your were not among them, sitting in the brand new science centre of the Norwegian Cancer Society, you may view them below:

 

Breakfast meeting on 27. September:
“Antibiotic resistance and cancer – current status, and how to prevent a potential apocalyptic scenario”:

Antibiotic resistance and cancer – Current status, and how to prevent a potential apocalyptic scenario #OIW2017

Posted by Kreftforeningen on Tuesday, September 26, 2017

 

Evening meeting 27. September:
“Cancer research and innovation – benefit for patients”:

Cancer research and innovation – benefit for patients #OIW2017

Posted by Kreftforeningen on Wednesday, September 27, 2017

 

Breakfast meeting 28. September:
How big data may transform the development of cancer treatments:

How Big Data may transform the development of cancer treatments #OIW2017

Posted by Kreftforeningen on Wednesday, September 27, 2017

 

 

 

PCI Biotech progressing positively

Our portfolio company PCI Biotech reports important progress in their half year presentation of 2017. The progress especially applies for the fimaCHEM programme , with early promising signs of effect in Phase I. The study has also provided encouraging interim overall survival data averaging 15.6 months per end July 2017 (median 14.4 months), with 25% of the patients still being alive.

 

 

These promising results may be further strengthened by repeating the treatment. Safety for repeated treatment will be investigated in a Phase I extension study and the first patient in this study was treated in August. Regulatory interactions to clarify the fastest way to market and subsequent preparations for Phase II will run in parallel with the extension study, thereby minimising time to initiation of a potential pivotal Phase II study with repeated treatment.

 “After the rapid initiation of the fimaCHEM Phase I extension study, we now have full focus on effective completion of this study and the regulatory interactions to clarify fastest route to market.  We are also eagerly awaiting the initial results on overall T-cell responses from the fimaVACC Phase I study and will revert to the market as soon as these are available,” comments CEO Per Walday.

Clinical translation of the fimaVACC asset is progressing with tolerability being established and the initial results on overall T-cell responses from the study are expected to be available during 2H 2017.

The fimaNAc programme has showed positive progress and the research collaborations with RXi Pharmaceuticals and a top-10 pharma company have both entered into new stages during 2017.

The rights issue completed in Q1 2017 enables PCI Biotech to progress the fimaChem programme through regulatory interactions to determine the fastest way to market, as well as the Phase I extension study and other preparations for initiation of Phase II. The proceeds, together with a grant from the Norwegian Research Council, will also cover the clinical translation of the promising fimaVACC asset. The organisation will be strengthened with Dr Olivecrona as Chief Medical Officer (CMO) from October 2017.

 

 

Highlights
fimaCHEM

  • Encouraging interim overall survival data from Phase I
  • First patient treated in the Phase I extension study

fimaVACC

  • Tolerability of the vaccination technology established – awaiting initial results on overall T-cell responses

fimaNAc

  • RXi Pharmaceuticals collaboration expanded into the field of immuno-oncology
  • Top-10 pharma collaboration extended and entered into in vivo studies

Corporate

  • Dr Hans Olivecrona appointed as Chief Medical Officer
  • Completed the fully underwritten rights issue of NOK 70 million
  • Awarded up to NOK 14.3 million in public grants for further development of the vaccination platform

 

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaCHEM programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVACCapplies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising Field.

 

Source: PCI Biotech

Come learn more about cancer

The Radium Hospital Research Foundation is part of the Oslo Innovation Week and Forskningsdagene with no less than three seminars on cancer together with the Norwegian Cancer Society, Oslo Cancer Cluster and IBM Norge

 

Come join us for updates from a broad range of Nordic experts on three vital topics related to cancer; the threat from antibiotic resistance, past and future innovations within cancer treatment and how Big Data may transform the way cancer treatments are developed. All seminars are free and open for all.

 

Wednesday 27.september 8:00 – 10:30 (am)
Breakfast meeting on “Antibiotic resistance and cancer”

Cancer patients need antibiotics to survive treatment. However, on the basis of some preliminary investigations, the knowledge of how antibiotic resistance will affect cancer treatment is limited.

Antibiotic resistance is considered one of the world’s biggest threats to public health. On a global scale, antibiotic resistance could mean 10 million annual deaths in the year 2030 according to WHO.

 

Wednesday 27. september 17:00 – 21:00 (pm)
Evening seminar on “Cancer innovation and benefit for patients”

Globally, nearly 1 in 6 deaths is due to cancer. The number of new cases is expected to rise by about 70% over the next 2 decades, according to the World Health Organisation, WHO. Even though the future may look look grim, more people than ever survive cancer due to new innovations within diagnostics, treatment and the use of technology.

Spend some time with us in the Norwegian Cancer Society’s Science Centre to get popular scientific, down to earth explanations from Nordic experts on what breakthroughs we will see within cancer care and treatment. We urge the audience to ask questions, comment and discuss with the presenters.

This event is supported by the Research Council of Norway.

 

Thursday 28.september 8:00 – 10:30 (am)
How Big Data may transform the development of cancer treatments

In this seminar we address how Big Data and data analytics may transform the way cancer treatments are developed. Is the use and implementation of technology based on Big Data the key to treat cancer in the near future? What are the benefit for the cancer patients? How may start-ups contribute? Can Norway adopt the Finnish model?

Representatives from Innovation Norway and Research Council in Norway and and the private sector, will debate how the public and private sector may work together to maximize the potential Big Data represents to drive innovations within the cancer field.